Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

507
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
507
Hormonal Regulation01:33

Hormonal Regulation

33.2K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Characterization of the Group A Streptococcus Virulence-Regulatory System FasBCAX.

Molecular microbiology·2025
Same author

Precision Reprogramming-Restoring Function to Aged Cells.

Cellular reprogramming·2025
Same author

The group A <i>Streptococcus</i> pathogenicity island RD2: virulence role and barriers to conjugative transfer.

Infection and immunity·2024
Same author

Influences of role models and other factors on physical activity amongst 6 to 16 years overweight and obese students.

Journal of family medicine and primary care·2024
Same author

Integrating population and single-cell variations in vaccine responses identifies a naturally adjuvanted human immune setpoint.

Immunity·2024
Same author

Telehealth Expansion, Internet Speed, and Primary Care Access Before and During COVID-19.

JAMA network open·2024

Related Experiment Video

Updated: Jul 15, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

861

ET-traps: Potential therapeutics for preeclampsia.

Arjun Jain1, Ira Jain2

  • 1ET-traps, Cambridge, UK; Department of Physiology, Development and Neuroscience, University of Cambridge, UK; Accelerate Cambridge, Judge Business School, University of Cambridge, UK; Imperial College London, UK.

Drug Discovery Today
|September 24, 2023
PubMed
Summary
This summary is machine-generated.

Endothelin-1 (ET-1) plays a role in preeclampsia. ET-traps, a novel therapy, effectively bind ET-1, reducing disease markers without toxicity, offering a potential treatment for preeclampsia.

Keywords:
ER stressET-trapscardiovascular complicationsendothelin-1oxidative stresspreeclampsiaproteinuria

More Related Videos

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

15.9K
Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

2.7K

Related Experiment Videos

Last Updated: Jul 15, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

861
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

15.9K
Mouse In Vivo Placental Targeted CRISPR Manipulation
07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

2.7K

Area of Science:

  • Cardiovascular Biology
  • Reproductive Medicine
  • Pharmacology

Background:

  • Elevated endothelin-1 (ET-1) is linked to preeclampsia pathogenesis.
  • ET-1 contributes to hypertension, oxidative stress, and organ damage in preeclampsia.

Purpose of the Study:

  • To explore the therapeutic potential of ET-traps for preeclampsia.
  • To evaluate the efficacy and safety of ET-traps in mitigating preeclampsia-associated pathologies.

Main Methods:

  • ET-traps, designed as Fc-fusion proteins mimicking ET-1 receptors.
  • Assessment of ET-trap binding affinity and sequestration of elevated ET-1.
  • Evaluation of ET-trap impact on preeclampsia markers and toxicity.

Main Results:

  • ET-traps demonstrate potent binding and sequestration of pathological ET-1.
  • Significant reduction in key preeclampsia markers observed.
  • No observed toxicity associated with ET-trap administration.

Conclusions:

  • ET-traps show promise as a novel therapeutic strategy for preeclampsia.
  • Targeting ET-1 with ET-traps may effectively manage preeclampsia symptoms and complications.
  • The therapy presents a safe and effective approach to reduce disease burden in preeclampsia.